文献速递血管炎

接受利妥昔单抗或环磷酰胺治疗的ANCA相关血管炎患者中耶氏肺孢子菌肺炎的发病率

Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-10-28

该研究利用TriNetX电子健康记录数据库(2011-2022年)识别接受利妥昔单抗或环磷酰胺诱导治疗的ANCA相关血管炎患者,计算诱导治疗前6个月及利妥昔单抗维持治疗期间耶氏肺孢子菌肺炎的发病率,并评估预防用药相关不良事件的风险。结果显示诱导治疗期间耶氏肺孢子菌肺炎发病率为每1000人年15.0例,无死亡;利妥昔单抗维持治疗期间发病率为每1000人年2.1例,其中1例死亡;预防用药与白细胞减少、皮疹和肾病风险升高相关。

要点

  • 诱导治疗期间耶氏肺孢子菌肺炎发病率为每1000人年15.0例,无死亡病例。
  • 利妥昔单抗维持治疗期间耶氏肺孢子菌肺炎发病率为每1000人年2.1例,其中1例死亡。
  • 接受预防用药者白细胞减少(HR 3.1)、皮疹(HR 1.9)和肾病(HR 2.6)风险高于未接受者。

核心结论

  • ANCA相关血管炎患者中耶氏肺孢子菌肺炎的发病率低于既往观察,利妥昔单抗维持治疗期间病例较少。
  • 耶氏肺孢子菌肺炎预防用药与不良事件相关。

研究设计与样本

  • 利用TriNetX电子健康记录数据库(2011年至2022年)识别因ANCA相关血管炎开始使用利妥昔单抗或环磷酰胺的患者。
  • 共纳入1461例ANCA相关血管炎病例,其中接受利妥昔单抗诱导治疗者占69.7%,环磷酰胺占18.9%,两者均用占11.4%。
  • 计算诱导治疗前6个月及利妥昔单抗维持治疗期间耶氏肺孢子菌肺炎的发病率,并采用Cox比例风险模型估计预防用药相关不良事件的风险比(HR)和置信区间(CI)。

主要发现

  • 诱导治疗期间共识别10例耶氏肺孢子菌肺炎,发病率为每1000人年15.0例,无死亡病例。
  • 利妥昔单抗维持治疗期间(n=709)共识别5例耶氏肺孢子菌肺炎,发病率为每1000人年2.1例,其中1例在因耶氏肺孢子菌肺炎诊断住院期间死亡。
  • 调整分析显示,接受预防用药者较未接受者白细胞减少风险升高(HR 3.1;95% CI 1.1-8.6),皮疹风险升高(HR 1.9;95% CI 1.0-3.6),肾病风险升高(HR 2.6;95% CI 1.3-5.1)。
  • 诱导治疗开始30天内处方预防用药包括甲氧苄啶-磺胺甲噁唑(30.7%)、阿托伐醌(5.4%)、氨苯砜(3.8%)和喷他脒(0.8%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This manuscript assesses the incidence of Pneumocystis jiroveci pneumonia (PJP) among patients receiving contemporary treatment regimens for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and adverse events associated with PJP prophylaxis. METHODS: Incident users of rituximab or cyclophosphamide for AAV were identified in the TriNetX electronic health records database from 2011 to 2022. The incidence rates (IRs) of PJP in the first 6 months of induction therapy with rituximab and/or cyclophosphamide and during postinduction maintenance therapy with rituximab were calculated. Cox proportional hazard models were used to estimate hazard ratios (HRs) and confidence intervals (CIs) for the risk of adverse events commonly associated with PJP prophylaxis. RESULTS: We identified 1,461 AAV cases who received induction therapy with rituximab (69.7%), cyclophosphamide (18.9%), or both (11.4%). Prophylaxis prescribed within 30 days of induction included trimethoprim-sulfamethoxazole (30.7%), atovaquone (5.4%), dapsone (3.8%), and pentamidine (0.8%). During induction therapy, 10 cases of PJP were identified (IR 15.0 cases per 1,000 patient-years); no deaths occurred. In adjusted analyses, those who received prophylaxis had a higher risk of leukopenia (HR 3.1; 95% CI 1.1-8.6), rash (HR 1.9; 95% CI 1.0-3.6), and nephropathy (HR 2.6; 95% CI 1.3-5.1) than those who did not. During rituximab maintenance therapy (n = 709), five cases of PJP were identified (IR 2.1 cases per 1,000 person-years), one of whom died during the hospitalization associated with a PJP diagnosis. CONCLUSION: Rates of PJP in patients with AAV were lower than previously observed, and few cases occurred during rituximab maintenance therapy. PJP prophylaxis was associated with adverse events.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Nettleton E, Sattui SE, Wallace Z, et al. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Arthritis Care Res (Hoboken). 2023. PMID: 37643919. doi:10.1002/acr.25222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。